FILING ANALYSIS · THURSDAY, NOVEMBER 12
Immix Biopharma, Inc. IMMX — 8-K: Results of Operations and Financial Condition
positive
Immix Biopharma reported a 89% complete response rate in its NEXICART-2 clinical trial, with potential to reach up to 98% complete response rate, and announced commercial launch preparation activities, including strengthened team and provider engagement. The company has $340.9 million in cash, expected to provide operating runway into mid-2028.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →